San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Aethlon Subsidiary to Collaborate With Thomas Jefferson University in Cancer Research

San Diego-based Aethlon Medical Inc., a company developing targeted therapeutic devices to address infectious diseases and cancer, announced that its majority-owned subsidiary Exosome Sciences Inc. has entered into a research collaboration with Thomas Jefferson University.

By Brittany Meiling April 3, 2015 1:04 p.m.   Share

Cos. Don’t Have to Pull the Plug After Clinical Trial Failures

MEDICINE: They Can Make Aggressive Cuts, Pursue Other Avenues

Those in the science business must learn to roll with the punches when clinical trials flop, especially when the companies are public, and the failures are broadcast on a global stage, industry veterans said.

Eli Lilly to Collaborate With Institute

Sanford-Burnham Medical Research Institute will collaborate with Eli Lilly and Co. to develop immunological therapies, the companies announced.

Tease photo

Foundry Medical Innovations Merging With Zeis to Become Toolbox Medical Innovations

Foundry Medical Innovations, a medical and diagnostic device development company in Carlsbad, has merged with Zeis Consulting Group, an IVD clinical research firm.

Cidara Therapeutics Reports Q1 Results

Cidara Therapeutics Inc. reported May 21 a net loss of $6.7 million for the first quarter of 2015, up from a net loss of $707,000 in the same quarter of last year.

Lpath to Cut Jobs After Eye Drug Fails Study

San Diego drug developer Lpath Inc. said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

Companion Medical Completes Series B Financing

Companion Medical Inc., a medical device company in San Diego, has announced the completion of a series B financing, led by an investment from Eli Lilly and Co.

Tandem Diabetes Announces That Its t:flex Insulin Pump Is on the Market

Tandem Diabetes Care Inc., a medical device company in San Diego, announced Tuesday that its t:flex Insulin Pump is on the market, with shipments planned in June.

Sevion Therapeutics Raises $3.02 Million in Equity Financing

Sevion Therapeutics Inc., a biopharmaceutical company developing therapies for cancer and immunological diseases, has raised $3.02 million in equity financing according to a recent statement filed with the Securities and Exchange Commission.

Fate Therapeutics Announces Proposed Public Offering of Common Stock

Fate Therapeutics, Inc., a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced that it has commenced an underwritten public offering of 6 million shares of its common stock.

Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer

Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, announced the appointment of Eric Loumeau as general counsel and chief compliance officer.

New Innovation Space Means Business When Selecting Startups

The Qualcomm Institute is launching a new innovation space at the University of California, San Diego with the capacity to house 15 to 20 seed-stage startups.

Tease photo

Isis Brings Big Pharma on Board for Its Antithrombotic Drug

BIOTECH: Deal With Bayer May Be Worth Up to $375 Million

Isis Pharmaceuticals has landed a megadeal with aspirin-maker Bayer AG to move a potential blockbuster drug from the lab to the market.

Tease photo


BIOTECH: Bioprinter Aims to Give L’Oreal Tissue for Product Testing

Organovo has landed a research partnership with beauty conglomerate L’Oreal to create 3-D bioprinted human skin to test cosmetics.

Tease photo

Sorrento Therapeutics Sells Cancer Drug and Subsidiary

In a deal potentially worth up to $1.3 billion, San Diego’s Sorrento Therapeutics has sold the rights to its proposed cancer treatment Cynviloq, as well as the wholly owned subsidiary that was developing the drug, to Illinois-based NantPharma.

Celladon to Cut Staff After Therapy Fails Key Trial

San Diego drug developer Celladon Corp. said it is laying off half of its staff to cut costs after its lead gene therapy to treat heart failure failed a key trial last month.